This is a preview of subscription content, log in via an institution to check access.
Rights and permissions
About this article
Cite this article
Infliximab plus methotrexate cost saving in RA. Pharmacoecon. Outcomes News 404, 5 (2003). https://doi.org/10.1007/BF03275993
Published:
Issue Date:
DOI: https://doi.org/10.1007/BF03275993